Becton Dickinson
BDX
$144.18
-2.26%
Becton, Dickinson and Co. (BD) is a global leader in the healthcare sector, operating primarily in the Medical - Instruments & Supplies industry as the world's largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company is a diversified medical technology giant with a distinct competitive identity built on a broad portfolio spanning BD Medical Essentials, Interventional, Connected Care, and Biopharma segments, which provides resilience and cross-selling opportunities across hospital and laboratory settings. The current investor narrative is dominated by the company's post-spinoff operational performance and its ability to navigate a challenging macroeconomic environment, with recent attention focused on its quarterly results, margin trajectory, and the strategic execution of its segmented business model in the face of potential healthcare spending pressures.…
BDX
Becton Dickinson
$144.18
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating: Hold. The core thesis is that BDX presents a classic 'value trap' scenario—its valuation appears cheap, but the deteriorating fundamentals and negative momentum warrant caution until a clear turnaround is evidenced.
Supporting evidence includes a forward P/E of 11.06x, which is deeply discounted and implies a significant earnings recovery. The company generates substantial free cash flow ($2.63B TTM) supporting its 3.6% dividend yield. However, revenue growth has decelerated to 1.63% YoY, margins are under pressure (Q1 gross margin of 44.63%), and the stock is in a severe downtrend, underperforming the market by over 30% in three months. Analyst sentiment is mixed, with firms like Citigroup maintaining a Buy while JP Morgan and Wells Fargo are Neutral.
The biggest risks are continued revenue deceleration and further margin compression invalidating the forward earnings estimates. This Hold rating would upgrade to a Buy if the stock stabilizes above the $127.59 support on strong volume and Q2 2026 shows a re-acceleration of revenue growth above 3% with expanding margins. It would downgrade to a Sell if revenue turns negative YoY or gross margin falls below 42%. Relative to its history and the muted growth profile, the stock is fairly valued to slightly undervalued, but not compellingly so without a fundamental catalyst.
Sign up to view all
BDX 12-Month Price Forecast
BDX is at an inflection point where its cheap valuation (11x forward earnings) conflicts with its weak growth trajectory and negative momentum. The base case of range-bound trading is most likely, as the company's strong cash flow and defensive profile provide a floor, while the lack of a visible growth catalyst caps the upside. The stance would upgrade to bullish on a confirmed breakout above $175 with improving volume, signaling the downtrend has broken. It would turn bearish on a breakdown below $127.59, which would suggest the fundamental deterioration is worse than priced in.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $187.43 and implied upside of +30.0% versus the current price.
Average Target
$187.43
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$115 - $187
Analyst target range
Analyst coverage for BDX appears limited based on the provided data, with only 6 analysts providing estimates for revenue and EPS, and no explicit consensus recommendation or average target price provided in the analyst data object. The estimated EPS average for the forward period is $16.53, with a narrow range from $16.42 to $16.72, indicating high conviction on near-term earnings, while estimated revenue averages $21.90 billion. Without a consensus price target, the implied upside or downside cannot be calculated, but the recent institutional ratings show a mix of Buy and Hold/Neutral stances. The range of recent analyst actions, as per institutional ratings, includes firms like Argus Research and Citigroup maintaining Buy ratings, while JP Morgan, Wells Fargo, and RBC Capital maintain Neutral or Sector Perform ratings. The clustering of several ratings around the February 10-11, 2026 period, coinciding with the earnings release and price gap down, suggests analysts are reassessing but not broadly downgrading the story. A wide target price range is not available, but the tight EPS estimate range signals stronger conviction on the bottom-line outcome despite top-line and macro uncertainties, whereas the lack of a published target price spread may indicate higher uncertainty on the appropriate multiple to apply.
Bulls vs Bears: BDX Investment Factors
The evidence currently tilts bearish, driven by severe technical deterioration, decelerating growth, and compressed margins. However, compelling bullish factors exist, primarily the deeply discounted forward valuation and strong cash generation. The single most important tension in the investment debate is whether the company's current challenges—reflected in the 1.63% revenue growth and margin pressure—are cyclical/transitory (supporting the bull case based on a forward P/E of 11x) or indicative of a more structural slowdown (validating the bearish price action). The resolution of this tension, visible in upcoming quarterly margin and growth figures, will determine the stock's direction.
Bullish
- Strong Free Cash Flow Generation: The company generated $2.63 billion in TTM free cash flow and $549 million in Q1 2026 alone. This robust cash generation provides financial flexibility for dividends, debt reduction, and strategic investments, supporting a sustainable 3.6% dividend yield.
- Attractive Forward Valuation: The forward P/E of 11.06x, based on estimated EPS of $16.53, is a significant discount to the trailing P/E of 19.76x. This implies the market has priced in a sharp earnings recovery, offering a compelling entry point if the company meets its forward estimates.
- Defensive, Low-Beta Profile: With a beta of 0.352, BDX is approximately 65% less volatile than the S&P 500. This characteristic makes it a potential defensive holding in uncertain markets, as evidenced by its stable revenue base fluctuating between $5.0B and $5.9B quarterly.
- Analyst Conviction on Bottom Line: Analyst EPS estimates for the forward period are tightly clustered between $16.42 and $16.72, indicating high conviction in the company's near-term earnings power. This consensus suggests underlying operational stability despite top-line headwinds.
Bearish
- Severe Price and Momentum Downtrend: The stock is down 26.62% over the last three months and 11.93% over the past year, severely underperforming the S&P 500 by over 40% on a 1-year basis. This negative momentum, including a sharp gap down post-Q1 earnings, reflects deep investor pessimism.
- Decelerating Revenue Growth: Q1 2026 revenue grew only 1.63% YoY, a significant deceleration from the 4.3% growth seen in Q4 2025. This sequential softness, with revenue fluctuating in a narrow band, raises concerns about the company's ability to re-accelerate top-line expansion.
- Compressed Profitability Margins: Q1 2026 gross margin of 44.63% was below the TTM average of 45.44%, and the net margin of 7.27% is modest. Operating margin of 11.31% also showed quarterly pressure, indicating the company is struggling to fully pass on cost inflation.
- Modest Returns on Capital: Return on Equity (ROE) of 6.61% and Return on Assets (ROA) of 4.08% are low, suggesting inefficient use of shareholder capital. This weak profitability profile limits the stock's appeal as a growth investment.
BDX Technical Analysis
The prevailing price trend for BDX is a pronounced downtrend, with the stock down 11.93% over the past year and a severe 26.62% decline over the last three months. The current price of $149.31 sits near the bottom of its 52-week range, approximately 15% above the 52-week low of $127.59 and 20% below the 52-week high of $187.35; this positioning near the lows suggests the stock is in a value-seeking zone but also reflects significant negative momentum that could indicate further fundamental concerns. Recent short-term momentum is decisively negative and accelerating the longer-term downtrend, with the stock down 4.50% over the past month and 26.62% over three months, a stark divergence from the S&P 500's positive returns of 9.98% and 4.14% over the same periods, respectively, highlighting severe relative weakness. Key technical support is clearly defined at the 52-week low area near $127.59, while resistance is established at the recent breakdown level and 52-week high near $187.35. A breakdown below the $127.59 support would signal a continuation of the bearish trend and potentially trigger a new leg down, whereas a sustained move above the $187.35 resistance would be needed to invalidate the current downtrend. The stock's beta of 0.352 indicates it is approximately 65% less volatile than the broader market (SPY), which is unusually low for a healthcare stock and suggests it has been acting as a defensive laggard rather than a growth vehicle, a factor that matters for investors seeking lower volatility but also limits upside participation in market rallies. The stock's relative strength metrics are deeply negative, with a 1-year relative strength of -40.97% against the SPY, underscoring its significant underperformance. The price action shows a sharp gap down on February 10, 2026, from over $207 to $171.68, which aligns with its Q1 2026 earnings release date and likely catalyzed the recent downtrend, creating a formidable overhead supply zone that will act as resistance. Volume data shows an average of approximately 2.47 million shares traded, but a spike would be needed to confirm any potential reversal from these oversold levels.
Beta
0.28
0.28x market volatility
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -7.2% | +8.2% |
| 3m | -18.9% | +9.0% |
| 6m | -25.3% | +10.5% |
| 1y | -17.8% | +26.5% |
| ytd | -26.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory shows modest growth but with signs of sequential softness; the most recent quarterly revenue (Q1 2026) was $5.25 billion, representing a year-over-year growth of 1.63%, which is a deceleration from the 4.3% growth seen in the prior quarter (Q4 2025 revenue of $5.89 billion). Analyzing the multi-quarter trend, revenue has fluctuated between $5.0 billion and $5.9 billion over the past two years, indicating stable but not accelerating top-line expansion, with the Life Sciences segment ($2.5B) slightly edging out the Medical segment ($2.4B) in the latest period, though specific growth rates by segment are not available. The company is profitable, with a net income of $382 million in Q1 2026, translating to a net margin of 7.27%. Gross margin for the quarter was 44.63%, which is below the trailing twelve-month gross margin of 45.44%, indicating some quarterly compression. Over recent quarters, gross margin has shown variability, ranging from a low of 42.81% in Q2 2025 to a high of 47.80% in Q3 2025, while operating margin in Q1 2026 was 11.31%, slightly below the TTM operating margin of 11.80%, suggesting stable but pressured profitability amidst cost inflation. Balance sheet and cash flow health is reasonable; the company generated $657 million in operating cash flow and $549 million in free cash flow in Q1 2026, contributing to a strong TTM free cash flow of $2.63 billion. The debt-to-equity ratio is 0.76, indicating a moderate level of financial leverage that is manageable for a company of its scale. Return on equity (ROE) is 6.61% and return on assets (ROA) is 4.08%, which are modest but positive, while the current ratio of 1.11 suggests adequate short-term liquidity to meet obligations.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.44%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given that Net Income is positive ($382M in Q1 2026), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 19.76x, while the forward PE is significantly lower at 11.06x, based on estimated EPS of $16.53; this substantial gap implies the market expects a meaningful recovery in earnings over the next twelve months, pricing in the recent profit weakness as temporary. Compared to industry averages, BDX's trailing PE of 19.76x is difficult to contextualize precisely without a provided sector average, but its Price-to-Sales (PS) ratio of 1.52x and EV/EBITDA of 10.39x appear reasonable for a mature, diversified medical technology company. The stock's Price-to-Book (PB) ratio of 1.31x suggests the market is valuing it close to its accounting equity, which is typical for asset-intensive industrials but may indicate limited growth premium expectations. In historical context, the current trailing PE of 19.76x is below the stock's own historical range observed in the data, which has seen peaks above 100x during periods of depressed earnings (e.g., Q4 2023) and more normalized levels in the mid-teens to low-20s. Trading near the lower end of its historical PE band suggests the market is pricing in cautious expectations, potentially viewing current challenges as more structural or prolonged, presenting a value opportunity if fundamentals stabilize.
PE
25.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~107x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability and growth stagnation. The Q1 2026 net margin of 7.27% and ROE of 6.61% are low, indicating the company is not efficiently converting revenue into shareholder returns. Revenue growth has decelerated to 1.63% YoY, and with 43% of sales international, the company faces FX volatility and potential healthcare spending pressures abroad. While the debt-to-equity ratio of 0.76 is manageable, the company's valuation remains dependent on demonstrating it can re-accelerate earnings to justify the forward P/E multiple.
Market & Competitive Risks include valuation compression and severe relative weakness. The stock's trailing P/E of 19.76x, while below its own historical peaks, could compress further if growth remains anemic, especially given its massive 40.97% underperformance vs. the S&P 500 over the past year. As a large-cap medical supplier, BDX faces constant pricing pressure and competition, which could further pressure its 44.63% gross margin. Its low beta of 0.352, while defensive, also means it may not participate in market rallies, leading to continued capital outflow if the 'risk-on' sentiment prevails.
Worst-Case Scenario involves a failure to stabilize operations, triggering a re-rating to distressed levels. A sequence of further earnings misses, margin degradation below 40%, and a dividend cut could break key technical support at the 52-week low of $127.59. Given the stock's 52-week high was $187.35 and the current price is $149.31, a breakdown could see it test the $120-$125 range, representing a potential downside of 16-20% from current levels. The historical max drawdown of -36.56% provides a precedent for such severe declines during periods of operational stress.
FAQ
The key risks are, in order of severity: 1) Operational: Continued deceleration of revenue growth below 1% and further compression of the 44.63% gross margin. 2) Technical & Sentiment: The severe downtrend and high short interest (short ratio 3.06) could lead to further selling pressure and delayed recovery. 3) Competitive & Macro: Pricing pressure in its core medical supplies market and potential cuts to hospital capital budgets in a weak economic environment. 4) Financial: While the debt level (D/E of 0.76) is manageable, a sustained earnings decline could pressure the dividend payout ratio of 71%.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $155 and $175 as the company stabilizes with low growth, supported by its cash flow. The Bull Case (25% probability) targets $187 to $200 on a successful operational turnaround and multiple expansion. The Bear Case (15% probability) warns of a drop to the $127-$140 range if fundamentals worsen. The Base Case is most likely, anchored by the analyst EPS consensus of $16.53 and a forward P/E near 11x. The key assumption is that revenue growth does not deteriorate further.
BDX appears fairly valued to slightly undervalued based on forward earnings, but the discount is justified by its challenges. The forward P/E of 11.06x is a steep discount to the trailing P/E of 19.76x, implying the market expects a sharp earnings recovery. Compared to its own historical P/E range, it trades at the lower end. The Price-to-Sales ratio of 1.52x and EV/EBITDA of 10.39x are reasonable for a mature medtech firm. The valuation implies the market expects low-single-digit growth and modest margins, which aligns with recent results, suggesting it is not dramatically mispriced.
BDX is a conditional buy only for specific investor profiles. For value-oriented, income-seeking investors with a multi-year horizon, the current price near 52-week lows and a 3.6% yield supported by strong free cash flow may be attractive. However, given the severe -26.62% three-month decline and decelerating 1.63% revenue growth, it is not a good buy for growth investors or those with a short-term horizon. The high short ratio of 3.06 also indicates significant skepticism. It becomes a more compelling buy only if upcoming quarters show operational stabilization.
BDX is unequivocally suitable for long-term investment only, with a suggested minimum holding period of 3-5 years. Its low beta of 0.352 and 3.6% dividend yield cater to patient investors seeking income and capital preservation. The severe negative momentum and lack of near-term growth catalysts make it a poor candidate for short-term trading. A long horizon allows time for a potential operational turnaround to materialize and for the discounted valuation to be recognized, while the dividend provides a return while waiting.